BARCLAYS

China Overseas Land & Investment Asset injection is just an extra gift

COLI has announced the long-awaited asset injection from its parent company, China State Construction Engineering Corp. Ltd. (CSCECL). The total consideration (including CSCECL loans) is about HK\$42.8bn to be settled by the issuance of 1.7bn new shares at a premium price of HK\$25.38 to CSCECL. Although the location of the landbank has yet to be provided, we believe the injection should further help to sustain COLI's consistent sales growth trend for the next few years. Our sensitivity analysis suggests possible NAV accretion of c10-13%, which should be an extra gift to COLI. We reiterate our OW rating and unchanged 12-month price target of HK\$27.70.

Details of the asset injection: On 24 March 2015, COLI announced that it is to acquire a total landbank of 10.9mn sqm of gross floor area from its parent company, CSCECL. The total consideration (including CSCECL loans) is to be about HK\$42.8bn, and COLI is to settle the payment by issuing 1.7bn new shares to its parent company at a premium price of HK\$25.38. Although the location of the landbank is yet to be disclosed, we believe the premium pricing implies that the parent company is optimistic on the outlook for COLI.

Possible NAV accretion of c10-13%: The proposed asset injection involves 27 projects in different development stages across Beijing, Shanghai, Tianjin, Chongqing, Suzhou, Chengdu, Xian, Urumqi, Changsha, Weifang and Zibo as well as three projects in London. Based on the assumptions in our sensitivity analysis, we estimate possible NAV accretion of c10-13% from these assets. As a reminder, 86% of the assets are in second- and third-tier cities while COLI said that it has adjusted the product mix over the past 18 months.

Reiterate OW: As we previously stated, we believe the asset injection is only a "plus" but not a "must" for COLI to sustain its earnings growth. Looking at its full-year results for 2014, COLI continued to demonstrate itself as the market leader with consistent earnings growth (+26% y/y), stable gross margins (34.3%) and healthy gearing levels (32.5%). This, in our view, should continue to support its premium valuation. As the announced asset injection has yet to be completed, we retain our 12-month NAV estimate at HK\$30.80 and, thus, our 12-month price target at HK\$27.70, which is at a 10% discount to the NAV. Downside risks include: 1) tighter measures in leading-tier cities; 2) slower contracted sales growth; and 3) lower margins than expected.

0688.HK: Financial and Valuation Metrics EPS HKD

FY Dec	2013	2014	2015	2016	2017
EPS	2.32A	2.92A	3.53E	4.17E	4.84E
Previous EPS	2.32A	2.78E	3.24E	3.93E	N/A
Consensus EPS	2.32A	2.81E	3.25E	3.70E	N/A
P/E	10.2	8.1	6.7	5.6	4.9

Source: Barclays Research.

Consensus numbers are from Thomson Reuters

Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report.

Investors should consider this report as only a single factor in making their investment decision.

This research report has been prepared in whole or in part by equity research analysts based outside the US who are not registered/qualified as research analysts with FINRA.

PLEASE SEE ANALYST CERTIFICATION(S) AND IMPORTANT DISCLOSURES BEGINNING ON PAGE 9.

Equity Research

Financial Services | Asia ex-Japan Real Estate 25 March 2015

Inductory View	Unchanged
Inductor () (in) (
Industry View	NEUTRAL
	Unchanged
Price Target	HKD 27.70
	Unchanged
Price (24-Mar-2015)	HKD 23.55
Potential Upside/Downside	+18%
Tickers	688 HK / 0688.HK
Market Cap (USD mn)	24818
Shares Outstanding (mn)	8173.98
Free Float (%)	46.69
52 Wk Avg Daily Volume (m	n) 24.7
52 Wk Avg Daily Value (USD	mn) 68.81
Dividend Yield (%)	2.4
Return on Equity TTM (%)	23.01
Current BVPS (HKD)	14.63
Source: Thomson Reuters	
Price Performance	Exchange-HKG
52 Week range	HKD 26.70-17.66
26 -	
24 -	Mour
22 -	
20 M m M	- V
18 -	
16 -	
Apr-2014 Jul-2014 Oct-201	.4 Jan-2015

Asia ex-Japan Real Estate

Alvin Wong

+852 2903 4535 alvin.wong@barclays.com Barclays Bank, Hong Kong

Jizhou Dong +852 2903 2482 jizhou.dong@barclays.com Barclays Bank, Hong Kong

Asia ex-Japan Real Estate

China Overseas Land & Investment (0688.HK)

Income statement (HKDmn)	2014A	2015E	2016E	2017E	CAGR
Revenue	119,997	119,047	138,136	157,115	9.4%
EBITDA	37,046	35,552	42,122	48,813	9.6%
EBIT	36,851	35,298	41,821	48,474	9.6%
Pre-tax income	38,498	41,489	49,114	56,565	13.7%
Net income	27,680	28,879	34,116	39,561	12.6%
EPS (reported) (HKD)	3.39	3.53	4.17	4.84	12.6%
Net income (adj)	23,851	28,879	34,116	39,561	18.4%
EPS (adj) (HKD)	2.92	3.53	4.17	4.84	18.4%
Diluted shares (mn)	8,174.5	8,174.0	8,174.0	8,174.0	0.0%
DPS (HKD)	0.55	0.71	0.83	0.97	20.7%
Profit growth (%)	25.84	21.08	18.14	15.96	-14.8%
Margin and return data					Average
EBITDA margin (%)	30.9	29.9	30.5	31.1	30.6
EBITDA margin (%) EBIT margin (%)	30.9 30.7	29.9 29.7	30.5 30.3	31.1 30.9	30.6 30.4
EBIT margin (%)	30.7	29.7	30.3	30.9	30.4
EBIT margin (%) Pre-tax margin (%)	30.7 26.8	29.7 31.2	30.3 31.6	30.9 32.1	30.4 30.4
EBIT margin (%) Pre-tax margin (%) Net margin (%)	30.7 26.8 23.1	29.7 31.2 24.3	30.3 31.6 24.7	30.9 32.1 25.2	30.4 30.4 24.3
EBIT margin (%) Pre-tax margin (%) Net margin (%) Net (adj) margin (%)	30.7 26.8 23.1 19.9	29.7 31.2 24.3 24.3	30.3 31.6 24.7 24.7	30.9 32.1 25.2 25.2	30.4 30.4 24.3 23.5
EBIT margin (%) Pre-tax margin (%) Net margin (%) Net (adj) margin (%) ROIC (%)	30.7 26.8 23.1 19.9 13.0	29.7 31.2 24.3 24.3 12.8	30.3 31.6 24.7 24.7 13.7	30.9 32.1 25.2 25.2 14.5	30.4 30.4 24.3 23.5 13.5
EBIT margin (%) Pre-tax margin (%) Net margin (%) Net (adj) margin (%) ROIC (%) ROA (%)	30.7 26.8 23.1 19.9 13.0 7.4	29.7 31.2 24.3 24.3 12.8 7.9	30.3 31.6 24.7 24.7 13.7 8.7	30.9 32.1 25.2 25.2 14.5 9.6	30.4 30.4 24.3 23.5 13.5 8.4
EBIT margin (%) Pre-tax margin (%) Net margin (%) Net (adj) margin (%) ROIC (%) ROA (%)	30.7 26.8 23.1 19.9 13.0 7.4 19.6	29.7 31.2 24.3 24.3 12.8 7.9	30.3 31.6 24.7 24.7 13.7 8.7	30.9 32.1 25.2 25.2 14.5 9.6	30.4 30.4 24.3 23.5 13.5 8.4
EBIT margin (%) Pre-tax margin (%) Net margin (%) Net (adj) margin (%) ROIC (%) ROA (%) ROE (%)	30.7 26.8 23.1 19.9 13.0 7.4 19.6	29.7 31.2 24.3 24.3 12.8 7.9	30.3 31.6 24.7 24.7 13.7 8.7	30.9 32.1 25.2 25.2 14.5 9.6	30.4 30.4 24.3 23.5 13.5 8.4 19.6
EBIT margin (%) Pre-tax margin (%) Net margin (%) Net (adj) margin (%) ROIC (%) ROA (%) ROE (%) Balance sheet and cash flow (HK	30.7 26.8 23.1 19.9 13.0 7.4 19.6 Dmn)	29.7 31.2 24.3 24.3 12.8 7.9 19.7	30.3 31.6 24.7 24.7 13.7 8.7 19.7	30.9 32.1 25.2 25.2 14.5 9.6 19.4	30.4 30.4 24.3 23.5 13.5 8.4 19.6 CAGR
EBIT margin (%) Pre-tax margin (%) Net margin (%) Net (adj) margin (%) ROIC (%) ROA (%) ROE (%) Balance sheet and cash flow (HK Tangible fixed assets	30.7 26.8 23.1 19.9 13.0 7.4 19.6 Dmn) 1,355	29.7 31.2 24.3 24.3 12.8 7.9 19.7 1,931	30.3 31.6 24.7 24.7 13.7 8.7 19.7 2,135	30.9 32.1 25.2 25.2 14.5 9.6 19.4 2,301	30.4 30.4 24.3 23.5 13.5 8.4 19.6 CAGR 19.3%
EBIT margin (%) Pre-tax margin (%) Net margin (%) Net (adj) margin (%) ROIC (%) ROA (%) ROE (%) Balance sheet and cash flow (HK Tangible fixed assets Intangible fixed assets	30.7 26.8 23.1 19.9 13.0 7.4 19.6 Dmn) 1,355 N/A	29.7 31.2 24.3 12.8 7.9 19.7 1,931 N/A	30.3 31.6 24.7 24.7 13.7 8.7 19.7 2,135 N/A	30.9 32.1 25.2 14.5 9.6 19.4 2,301 N/A	30.4 30.4 24.3 23.5 13.5 8.4 19.6 CAGR 19.3% N/A

Total assets	350,937	378,705	409,645	411,378	5.4%
Short and long-term debt	94,532	95,446	88,052	76,784	-6.7%
Net debt/(funds)	43,317	35,866	17,308	2,344	-62.2%
Other long-term liabilities	6,229	5,305	5,305	5,305	-5.2%
Total liabilities	214,129	216,744	218,973	187,630	-4.3%
Shareholders' equity	133,334	159,503	187,603	220,070	18.2%
Change in working capital	-30,628	-4,020	-1,006	-10,973	N/A
Cash flow from operations	-15,233	26,036	28,929	24,707	N/A
Capital expenditure	-4,321	-4,444	-4,355	-2,648	N/A
Free cash flow	-19,554	21,592	24,574	22,059	N/A
BVPS (HKD)	16.31	19.51	22.95	26.92	18.2%

Valuation and leverage metrics					Average
P/E (reported) (x)	7.0	6.7	5.6	4.9	6.0
P/E (adj) (x)	8.1	6.7	5.6	4.9	6.3
NAV per share (HKD)	30.80	35.60	30.90	28.30	31.40
Premium/(discount) to NAV (%)	-33.9	-42.8	-34.1	-28.1	-34.7
P/BV (x)	1.4	1.2	1.0	0.9	1.1
Dividend yield (%)	2.3	3.0	3.5	4.1	3.2
Net debt/equity (%)	32.5	22.5	9.2	1.1	16.3
Net debt/EBITDA (x)	1.2	1.0	0.4	0.0	0.7
Total debt/capital (%)	40.9	37.1	31.6	25.5	33.8

Source: Company data, Barclays Research

Note: FY End Dec

Industry View: NEUTRAL

Stock Rating: OVERWEIGHT

Pric	e (24-	Mar-2015)			НК	D	23.55
Pric	e Targ	et			HK	D	27.70
	~				1		

Why Overweight? Despite significant volatility in the China property sector overall, we believe COLI is an appropriate long-term investment. We see the following positive catalysts: 1) a smooth management succession, which would remove a key overhang; and 2) a potential asset injection, which we believe signals strong support for COLI from CSCECL.

Upside case HKD 32.30

Should home-buyers' liquidity remain supportive and the government not undertake further propertycooling measures, sales momentum should be boosted and NAV discounts should narrow. In our upside case, we assume COLI trades at 5% premium to NAV.

Downside case

HKD 18.50

Unexpected administrative tightening measures, especially on the demand side, and a hard-landing for China's macro-economy could depress valuations, in our view. In our downside case, we assume a 40% discount to NAV for COLI.

Upside/Downside scenarios



The long-awaited asset injection is announced

COLI has announced that it is to acquire assets from its parent company, China State Construction Engineering Corp. Ltd. (CSCECL), which is a controlling shareholder of COLI through its interest in China Overseas Holdings Ltd. (COHL). The consideration was determined at RMB1,824mn (or HK\$2,309mn), and COLI will also assume the CSCECL loans related to the asset injection totalling RMB31,993mn (or HK\$40,497mn). The total consideration amounts to RMB33,817mn (or HK\$42,806mn) for which COHL has agreed to subscribe to 1,687mn subscription shares (20.6% of the existing issued share) at the subscription price of HK\$25.38, a 10.8% premium to the close price on 23 March. After the injection, COHL, together with its wholly own subsidiary, Silver Lot Development Ltd., will have a controlling interest in 6,033mn shares, representing 61.2% of the enlarged share capital.

FIGURE 1

COLI - shareholder changes with the asset injection

	As at the date of	announcement	Immediately after the subscription completion			
Name of shareholder	Number of Shares held	Appr % of total issued share	Number of Shares held	Appr % of total issued share		
COHL	3,837,380,380	46.95%	5,523,986,255	56.02%		
Silver Lot (wholly owned by COHL)	509,136,928	6.23%	509,136,928	5.16%		
Public shareholders	3,827,458,198	46.82%	3,827,458,198	38.82%		
Total	8,173,975,506	100%	9,860,581,381	100%		

Source: Company data, Barclays Research

According to COLI, the assets involved include 27 project projects in various major cities in the Mainland China, including Beijing, Shanghai, Tianjin, Chongqing, Suzhou, Chengdu, Xian, Urumqi, Changsha, Weifang and Zibo as well as three property projects in London. In terms of city tiers (stripping out London), only 14% of the landbank is located in first-tier cities while 55% and 31% are in second- and third-tier cities. COLI has not provided any additional details about the development stages of these assets. However, the company indicated that some projects have been completed and will be kept for rental purposes.

FIGURE 3

FIGURE 2

COLI - details of landbank to be acquired

City	Approximate total GFA ('000 sq.m.)	Target Group's shareholdings
Beijing	1,025	80% - 100%
Shanghai	555	50% - 100%
Tianjin	280	90%
Chongqing	2,316	100%
Suzhou	30	100%
Chengdu	386	41% - 50%
Xi'an	750	70% - 100%
Urumqi	1,620	60%
Changsha	573	95%
Weifang	2,325	100%
Zibo	1,009	100%
London	48	100%
Total	10,917	

Source: Company data, Barclays Research

COLI – landbank to be acquired by city-tier 1st-tier 3rd-tier 31%

2nd-tier 55%

Source: Company data, Barclays Research

Our sensitivity analysis suggests possible NAV accretion of c10-13%

Given the lack of details about the types of property projects (residential and commercial) and their development schedules, we made several assumptions to test the NAV impact generated from such a sizable asset injection.

- We assume the entire landbank of 10.9mn sqm of gross floor area will be equally sold and delivered over the next five years (i.e. no projects will be kept for rental purpose).
- We assume the average selling price to be 80% of COLI's contracted average selling price of HK\$14,984/sqm given its higher exposure to second- and third-tier cities.
- We use a discounted cash-flow analysis to value the entire landbank, assuming a WACC of 11.4%, under different assumptions of net profit margins ranging from 12-20%.
- We add back the acquisition cost of HK\$42.8bn.

In reality, the increase in new shares could lower COLI's existing NAV (before the asset injection). However, we believe COLI, after spending more than 18 months adjusting the product mix of its parent company's landbank, could create good value from those injected assets. We expect a minimum NAV accretion of HK\$5.64/share from the asset injection (based on net profit margin of 12%) while COLI's strong operating record may lead to an even higher NAV accretion of HK\$6.50/share (based on net profit margin of 20%). This suggests possible NAV accretion of c-10-13%, on our estimates.

FIGURE 4

		16	18	20
3,141	3,664	4,188	4,711	5,235
3,141	3,664	4,188	4,711	5,235
3,141	3,664	4,188	4,711	5,235
3,141	3,664	4,188	4,711	5,235
3,141	3,664	4,188	4,711	5,235
12,802	14,936	17,069	19,203	21,337
42,806	42,806	42,806	42,806	42,806
5.64	5.86	6.07	6.29	6.50
28.30	28.30	28.30	28.30	28.30
33.94	34.16	34.37	34.59	34.80
10%	11%	12%	12%	13%
	3,141 3,141 3,141 3,141 12,802 42,806 5,64 28,30 33,94	3,141 3,664 3,141 3,664 3,141 3,664 3,141 3,664 3,141 3,664 12,802 14,936 42,806 42,806 5.64 5.86 28.30 28.30 33.94 34.16	3,141 3,664 4,188 3,141 3,664 4,188 3,141 3,664 4,188 3,141 3,664 4,188 3,141 3,664 4,188 3,141 3,664 4,188 12,802 14,936 17,069 42,806 42,806 42,806 5.64 5.86 6.07 28.30 28.30 28.30 33.94 34.16 34.37	3,141 3,664 4,188 4,711 3,141 3,664 4,188 4,711 3,141 3,664 4,188 4,711 3,141 3,664 4,188 4,711 3,141 3,664 4,188 4,711 3,141 3,664 4,188 4,711 3,141 3,664 4,188 4,711 12,802 14,936 17,069 19,203 42,806 42,806 42,806 42,806 5.64 5.86 6.07 6.29 28.30 28.30 28.30 28.30 33.94 34.16 34.37 34.59

COLI – sensitivity analysis regarding landbank to be acquired

Source: Company data, Barclays Research

OW: Asset injection is just an extra gift to its solid fundamentals

As we have previously stated, we believe that the asset injection is only a "plus" but not a "must" for COLI to sustain its earning growths. Indeed, COLI has continued to demonstrate itself as the market leader in the China property sector with consistent earning growth, stable gross margins and healthy gearing levels. It may be challenging for COLI to acquire some landbank from its parent company in lower-tier cities. However, we believe its strong operating record with low funding cost of 4.3% should continue to generate good margins there. To some extent, we do not rule out any possibility of another round of asset injections in which COLI could dispose of all its landbank in these lower-tier cities to group company China Overseas Grand Ocean (COGO), which focuses on property development in third- and fourth-tier cities and of which COLI owns a 37.9% stake.

Price target valuation: Given that the announced asset injection has yet to be completed, we maintain our 12-month NAV estimate at HK\$30.80 and our 12-month price target remains unchanged at HK\$27.70, which is based on a 10% discount to our NAV estimate.

Key risks: The key downside risks to our price target, in our view, include the following: 1) tighter measures in leading-tier cities than we expect; 2) slower contracted sales growth than we expect; and 3) lower margin than we expect.


2014 results highlights

- Core earnings increased by 26% y/y to HK\$23.9bn. COLI's core profit and EPS increased by 26% y/y to HK\$23.9bn and HK\$2.92 in 2014, respectively. This was mainly driven by a 46% y/y growth in top-line revenue.
- Development margin remained intact at 34.3%. During the period, COLI's gross margin was increased by 2ppt to 34.5% in 2014. The development margin, stripping out the profit contribution from those affordable housing projects, came in at 34.3% for 2014. This was slightly lower than 35.1% for 2013 but still within the company's guidance of 33-35%.
- Net gearing was healthy at 32.5% at end-2014. COLI reported net gearing of 32.5% at end-2014, which was the lowest in the sector. Among its total debt of HK\$94.5bn, debt denominated in USD, HKD and RMB accounted for 51.5%, 30.5% and 18% of total debt, respectively. During the period, the company had cash of HK\$51.2bn but 1-year short-term debt of only HK\$22.5bn.
- Full-year dividend was up 17% y/y at 55 HK cents. The company proposed a final dividend of 35 HK cents. This, alongside an interim dividend of 20 HK cents, brought its full-year dividend to 55 HK cents. This represented a y/y increase of 17% and a dividend payout ratio of 19%. Based on the closing price of HK\$23.55 on 24 March 2015, the implied dividend yield was 2.3%.
- 2015 contracted sales target set at HK\$168bn. With saleable resources of about HK\$250bn (including new resources of HK\$170bn), COLI aims to achieve full-year contracted sales of HK\$168bn, representing a 19.3% y/y increase. Its completed inventory level remained low at ~HK\$450bn, and the company does not expect to massively adjust the price.

COLI – results summary			
As of end	Dec-14	Jun-14	h/h chg
BVPS (HK\$)	16.31	14.63	12%
Net debt (HK\$mn)	43,317	44,510	-3%
Net gearing (%)	32.5%	37.2%	-5ppts
For the period ended	Dec-14	Dec-13	y/y chg
Contracted sales (HK\$mn)	140,809	138,520	2%
Revenue (HK\$mn)	119,997	82,469	46%
Core profit (HK\$mn)	23,851	18,953	26%
Core EPS (HK\$)	2.92	2.32	26%
DPS (HK\$)	0.55	0.47	17%
Core proft margin (%)	19.9%	23.0%	-3ppts


FIGURE 5






Source: Company data, Barclays Research


FIGURE 8






Source: Company data, Barclays Research estimates


FIGURE 10






Source: Company data, Barclays Research estimates

FIGURE 7





Source: Company data, Barclays Research estimates





FIGURE 11

COLI - book value per share and net gearing



Source: Company data, Barclays Research estimates

FIGURE 12


COLI – company description


China Overseas Land & Investment (COLI), listed on the HKSE in August 1992, is 53.2% owned by the Shanghailisted state-owned China State Construction Engineering Corp. Ltd. (CSCECL). The company is one of the biggest China property developers (in terms of market cap), holding a total landbank of 37mn sqm of gross floor area across first- and second-tier cities in China, excluding area owned directly by COGO. COLI also owns a 37.9% interest in China Overseas Grand Oceans (COGO), which primarily focuses on property development in lower-tier cities in China.











Source: Company data, Bloomberg, Barclays Research estimates

FIGURE 13

COLI – five-factor analysis






FIGURE 17

COLI – profit and loss (in HKDmn except for per share)

Year ended 31 Dec	FY12A	FY13A	FY14A	FY15E	FY16
Turnover	64,581	82,469	119,997	130,571	151,500
Operating activities:					
Property sales	22,854	24,381	36,595	38,521	45,368
Property rentals	496	766	865	862	1,219
Others	-279	-788	-608	-583	-642
EBIT	23,072	24,358	36,851	38,800	45,94
Net interest	27	248	69	447	579
Associates and JCEs	2,637	3,773	1,599	2,243	2,589
Exceptionals	35	1,471	-21	0	(
PBT	25,771	29,851	38,498	41,489	49,114
Taxes	-9,859	-9,292	-14,143	-11,970	-14,38
MI	-110	-135	-525	-641	-61
PAT	15,802	20,424	23,830	28,879	34,110
Net IP revaluation	2,920	2,620	3,850	0	
Reported profit	18,722	23,044	27,680	28,879	34,110
Barclays core profit (adj.)	15,767	18,953	23,851	28,879	34,110
Reported EPS (HKD)	2.29	2.82	3.39	3.53	4.13
Barclays core EPS (HKD)	1.93	2.32	2.92	3.53	4.1
Barclays core margin (%)	24.4	23.0	19.9	22.1	22.5
bareia) 5 core margin (70)					

FIGURE 19

COLI – balance sheet (in HKDmn except for per share)

Balance Sheet (HKDmn)					
Year ended 31 Dec	FY12A	FY13A	FY14A	FY15E	FY16E
Non-current assets	49,557	55,307	66,916	71,466	78,110
Investment properties	23,657	32,532	44,755	44,138	47,988
Associates and JCEs	17,211	15,949	15,748	19,943	22,532
Others	8,689	6,826	6,413	7,386	7,590
Current assets	180,268	241,216	284,021	307,239	331,536
Properties under development	94,120	160,952	194,956	179,658	187,483
Completed properties for sales	14,360	0	0	31,704	33,085
Others	30,907	38,852	37,850	36,295	40,224
Cash	40,880	41,411	51,215	59,581	70,743
Total assets	229,825	296,522	350,937	378,705	409,645
Current liabilities	83,975	110,928	135,910	125,537	134,421
ST loans	5,546	3,303	22,542	9,545	8,805
Others	78,430	107,625	113,368	115,992	125,616
Shareholders ' fund	87,244	109,971	133,334	159,503	187,603
мі	313	1,080	3,474	2,458	3,069
Non-current liabilities	58,292	74,544	78,219	91,207	84,551
LT loans	53,243	69,397	71,990	85,902	79,247
Others	5,049	5,147	6,229	5,305	5,305
BVPS (HKD)	10.68	13.46	16.31	19.51	22.95
Net gearing (%)	20.5	28.5	32.5	22.5	9.2

Source: Company data, Barclays Research estimates

FIGURE 21

COLI – cash flow statement (HKDmn except for per share)

FY12A	FY13A	FY14A	FY15E	FY16E
29,422	33,289	38,498	41,489	49,114
-3,598	-3,329	-3,655	254	301
-2,637	-3,773	-1,751	-2,243	-2,589
-7,946	-24,705	-30,628	-4,020	-1,006
1	2	3	4	4
-8,153	-9,741	-10,343	-11,970	-14,387
-39	-1,829	-7,357	2,521	-2,508
7,050	-10,086	-15,233	26,036	28,929
-1,690	-4,558	-4,321	-4,444	-4,355
3,196	3,497	158	1,197	C
8,556	-11,147	-19,396	22,788	24,574
0	0	0	0	C
11,104	11,524	0	0	C
5,045	2,112	36,697	-7,542	-4,545
-2,648	-2,478	-7,677	-7,444	-8,866
22,056	11	9,624	7,802	11,163
17,841	39,880	40,876	51,243	59,045
-18	985	744	0	C
39,880	40,876	51,243	59,045	70,208
		-2.37		3.01
	29,422 -3,598 -2,637 -7,946 1 -8,153 -39 7,050 -1,690 3,196 8,556 0 11,104 5,045 -2,648 22,056 17,841 -18	29,422 33,289 -3,598 -3,329 -2,637 -3,773 -7,946 -24,705 1 2 -8,153 -9,741 -39 -1,829 7,050 -1,630 -1,650 -4,558 3,196 3,497 8,556 -11,147 0 0 01,1,104 11,524 5,045 2,112 -2,648 -2,478 22,056 11 17,841 39,880 -18 985	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

Source: Company data, Barclays Research estimates

FIGURE 18

GAV breakdown	Current	% of GAV	End-2014	% of GAV
Development properties				
Mainland China	269,270	87%	263,905	86%
HK & Macau	22,685	7%	21,100	7%
Investment properties				
Commercial	7,512	2%	10,253	3%
Office	7,126	2%	8,651	3%
HK & Macau	1,585	1%	1,633	1%
Total gross asset value (GAV)	308,179	100%	305,542	100%
Net debt (incl. o/s land premium)	-80,606		-53,503	
Net asset value (NAV)	227,573		252,039	
# of shares outstanding (mn)	8,173		8,173	
NAV per share (in HKD)	27.80		30.80	

Source: Company data, Barclays Research estimates





FIGURE 22

COLI - relative share price performances



Source: Company data, Bloomberg, Barclays Research estimates

ANALYST(S) CERTIFICATION(S):

I, Alvin Wong, hereby certify (1) that the views expressed in this research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

IMPORTANT DISCLOSURES

Barclays Research is a part of the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays"). For current important disclosures regarding companies that are the subject of this research report, please send a written request to: Barclays Research Compliance, 745 Seventh Avenue, 14th Floor, New York, NY 10019 or refer to http://publicresearch.barclays.com or call 212-526-1072.

The analysts responsible for preparing this research report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by investment banking activities.

Research analysts employed outside the US by affiliates of Barclays Capital Inc. are not registered/qualified as research analysts with FINRA. These analysts may not be associated persons of the member firm and therefore may not be subject to NASD Rule 2711 and incorporated NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst's account.

Analysts regularly conduct site visits to view the material operations of covered companies, but Barclays policy prohibits them from accepting payment or reimbursement by any covered company of their travel expenses for such visits.

In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer to https://live.barcap.com/publiccp/RSR/nyfipubs/disclaimer/disclaimer/disclaimer-research-dissemination.html. In order to access Barclays Research Conflict Management Policy Statement, please refer to: https://live.barcap.com/publiccp/RSR/nyfipubs/disclaimer/conflict-management.html.

The Investment Bank's Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise.

Primary Stocks (Ticker, Date, Price)

China Overseas Land & Investment (0688.HK, 24-Mar-2015, HKD 23.55), Overweight/Neutral, J

Materially Mentioned Stocks (Ticker, Date, Price)

China Overseas Grand Oceans Group (0081.HK, 24-Mar-2015, HKD 3.60), Underweight/Neutral, J

Disclosure Legend:

A: Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of the issuer in the previous 12 months.

B: An employee of Barclays Bank PLC and/or an affiliate is a director of this issuer.

C: Barclays Bank PLC and/or an affiliate is a market-maker and/or liquidity provider in equity securities issued by this issuer or one of its affiliates.

D: Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from this issuer in the past 12 months.

E: Barclays Bank PLC and/or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer within the next 3 months.

F: Barclays Bank PLC and/or an affiliate beneficially owned 1% or more of a class of equity securities of the issuer as of the end of the month prior to the research report's issuance.

G: One of the analysts on the coverage team (or a member of his or her household) owns shares of the common stock of this issuer.

H: This issuer beneficially owns 5% or more of any class of common equity securities of Barclays Bank PLC.

I: Barclays Bank PLC and/or an affiliate has a significant financial interest in the securities of this issuer.

J: Barclays Bank PLC and/or an affiliate trades regularly in the securities of this issuer.

K: Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation from this issuer within the past 12 months.

L: This issuer is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.

M: This issuer is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or an affiliate.

N: This issuer is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC and/or an affiliate.

O: Barclays Capital Inc., through Barclays Market Makers, is a Designated Market Maker in this issuer's stock, which is listed on the New York Stock Exchange. At any given time, its associated Designated Market Maker may have "long" or "short" inventory position in the stock; and its associated Designated Market Maker may be on the opposite side of orders executed on the floor of the New York Stock Exchange in the stock.

P: A partner, director or officer of Barclays Capital Canada Inc. has, during the preceding 12 months, provided services to the subject company for remuneration, other than normal course investment advisory or trade execution services.

Q: Barclays Bank PLC and/or an affiliate is a Corporate Broker to this issuer.

R: Barclays Capital Canada Inc. and/or an affiliate has received compensation for investment banking services from this issuer in the past 12 months.

S: Barclays Capital Canada Inc. is a market-maker in an equity or equity related security issued by this issuer.

T: Barclays Bank PLC and/or an affiliate is providing equity advisory services to this issuer.

Risk Disclosure(s)

Master limited partnerships (MLPs) are pass-through entities structured as publicly listed partnerships. For tax purposes, distributions to MLP unit holders may be treated as a return of principal. Investors should consult their own tax advisors before investing in MLP units.

Guide to the Barclays Fundamental Equity Research Rating System:

Our coverage analysts use a relative rating system in which they rate stocks as Overweight, Equal Weight or Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry (the "industry coverage universe").

In addition to the stock rating, we provide industry views which rate the outlook for the industry coverage universe as Positive, Neutral or Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.

Stock Rating

Overweight - The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Equal Weight - The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12month investment horizon.

Underweight - The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12-month investment horizon.

Rating Suspended - The rating and target price have been suspended temporarily due to market events that made coverage impracticable or to comply with applicable regulations and/or firm policies in certain circumstances including where the Investment Bank of Barclays Bank PLC is acting in an advisory capacity in a merger or strategic transaction involving the company.

Industry View

Positive - industry coverage universe fundamentals/valuations are improving.

Neutral - industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.

Negative - industry coverage universe fundamentals/valuations are deteriorating.

Below is the list of companies that constitute the "industry coverage universe":

Asia ex-Japan Real Estate

Agile Property Holdings (3383.HK)	Ananda Development PCL (ANAN.BK)	Ascendas REIT (AEMN.SI)
CapitaCommercial Trust (CACT.SI)	CapitaLand (CATL.SI)	CapitaMall Trust (CMLT.SI)
Champion REIT (2778.HK)	China Overseas Grand Oceans Group (0081.HK)	China Overseas Land & Investment (0688.HK)
China Resources Land (1109.HK)	Chong Hong Construction Co. (5534.TW)	City Developments (CTDM.SI)
CKH Holdings (0001.HK)	Country Garden Holdings (2007.HK)	DLF Ltd. (DLF.NS)
Evergrande Real Estate Group (3333.HK)	Far Eastern New Century Corp. (1402.TW)	Farglory Land Development Co., Ltd. (5522.TW)
Fortune REIT (0778.HK)	Global Logistic Properties (GLPL.SI)	Godrej Properties Ltd. (GODR.NS)
Greentown China Holdings Ltd. (3900.HK)	Guangzhou R&F Properties Co., Ltd. (2777.HK)	Hang Lung Properties (0101.HK)
Henderson Land (0012.HK)	Hongkong Land (HKLD.SI)	Huaku Development Co., Ltd. (2548.TW)
Hui Xian REIT (87001.HK)	Hysan Development (0014.HK)	IREIT Global (IREI.SI)
Keppel Land (KLAN.SI)	Keppel REIT (KASA.SI)	Kerry Properties (0683.HK)
Kindom Construction (2520.TW)	KWG Property Holding (1813.HK)	Link REIT (0823.HK)
Longfor Properties (0960.HK)	Mapletree Industrial Trust (MAPI.SI)	Mapletree Logistics Trust (MAPL.SI)
Midland Holdings (1200.HK)	New World Development (0017.HK)	Oberoi Realty Ltd. (OEBO.NS)
Poly Property Group Co., Ltd. (0119.HK)	Prestige Estates Projects Ltd. (PREG.NS)	Shimao Property Holdings Ltd. (0813.HK)
Sino Land (0083.HK)	Sino-Ocean Land Holdings Ltd. (3377.HK)	Sobha Developers Ltd. (SOBH.NS)
Sun Hung Kai Properties (0016.HK)	Sunac China Holdings Ltd. (1918.HK)	Suntec REIT (SUNT.SI)
Swire Properties (1972.HK)	Wharf Holdings (0004.HK)	Yuexiu REIT (0405.HK)

Distribution of Ratings:

Barclays Equity Research has 2704 companies under coverage.

43% have been assigned an Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Buy rating; 54% of companies with this rating are investment banking clients of the Firm.

41% have been assigned an Equal Weight rating which, for purposes of mandatory regulatory disclosures, is classified as a Hold rating; 46% of companies with this rating are investment banking clients of the Firm.

14% have been assigned an Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Sell rating; 42% of companies with this rating are investment banking clients of the Firm.

Guide to the Barclays Research Price Target:

Each analyst has a single price target on the stocks that they cover. The price target represents that analyst's expectation of where the stock will trade in the next 12 months. Upside/downside scenarios, where provided, represent potential upside/potential downside to each analyst's price target over the same 12-month period.

Top Picks:


Barclays Equity Research's "Top Picks" represent the single best alpha-generating investment idea within each industry (as defined by the relevant "industry coverage universe"), taken from among the Overweight-rated stocks within that industry. Barclays Equity Research publishes global and regional "Top Picks" reports every quarter and analysts may also publish intra-quarter changes to their Top Picks, as necessary. While analysts may highlight other Overweight-rated stocks in their published research in addition to their Top Pick, there can only be one "Top Pick" for each industry. The current list of Top Picks is available on https://live.barcap.com/go/RSL/servlets/dv.search?pubType=4526&contentType=latest.

To see a list of companies that comprise a particular industry coverage universe, please go to http://publicresearch.barclays.com.

Barclays offices involved in the production of equity research:

London Barclays Bank PLC (Barclays, London) New York Barclays Capital Inc. (BCI, New York) Tokyo Barclays Securities Japan Limited (BSJL, Tokyo) São Paulo Banco Barclays S.A. (BBSA, São Paulo) Hong Kong Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong) Toronto Barclays Capital Canada Inc. (BCCI, Toronto) Johannesburg Absa Bank Limited (Absa, Johannesburg) Mexico City Barclays Bank Mexico, S.A. (BBMX, Mexico City) Taiwan Barclays Capital Securities Taiwan Limited (BCSTW, Taiwan) Seoul Barclays Capital Securities Limited (BCSL, Seoul) Mumbai Barclays Securities (India) Private Limited (BSIPL, Mumbai) Singapore Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)

China Overseas Land & Investment (688 HK / 0688.HK)



OVERWEIGH	т		NEUTRAL		
Currency=HI	Currency=HKD				
Date	Closing Price	Rating	Adjusted Price Target		
31-Jul-2014	23.80		27.70		
14-Mar-2014	18.92		28.60		
12-Nov-2013	23.10	Overweight	26.80		
28-Aug-2013	3 22.50	Drop Coverage			
30-May- 2013	22.95		29.07		
21-May- 2013	24.00	Overweight	29.08		
28-Feb-2013	23.55		24.00		
19-Oct-2012	20.25		19.00		
18-May- 2012	14.80	Equal Weight	15.37		

Industry View

Source: Thomson Reuters, Barclays Research

Historical stock prices and price targets may have been adjusted for stock splits and dividends.

J: Barclays Bank PLC and/or an affiliate trades regularly in the securities of China Overseas Land & Investment.

Valuation Methodology: Our target price of HK\$27.70 is based on a 10% discount to our end-2014E NAV estimate of HK\$30.80, which translates into 10.0x FY14E P/E.

Stock Rating

Risks which May Impede the Achievement of the Barclays Research Price Target: Downside risks to our price target include: 1) mismatch of asset injection from the parent company; and 2) slower-than-expected contracted sales growth; and 3) lower-than-expected margin.

China Overseas Grand Oceans Group (81 HK / 0081.HK)



UNDERWEIGHT NEUTRAL			
Currency=HKD			
Date	Closing Price	Rating	Adjusted Price Target
03-Dec-2014	4.24		3.90
31-Jul-2014	6.29		5.30
03-Mar-2014	5.30		5.50
12-Nov-2013	8.85	Underweight	7.30
28-Aug-2013	9.75	Drop Coverage	
21-May- 2013	11.84		15.11
28-Feb-2013	10.90	Overweight	12.30
19-Oct-2012	8.17		7.50
04-Jun-2012	6.31		6.03
18-May- 2012	5.97	Equal Weight	6.03

Industry View

Source: Thomson Reuters, Barclays Research

Stock Rating

Historical stock prices and price targets may have been adjusted for stock splits and dividends.

J: Barclays Bank PLC and/or an affiliate trades regularly in the securities of China Overseas Grand Oceans Group.

Valuation Methodology: Our target price of HK\$3.90 is based on a 60% discount to our forward NAV estimate of HK\$9.80, which translates into 3.0x FY15 P/E.

Risks which May Impede the Achievement of the Barclays Research Price Target: Upside risks to our target price include: 1) stronger-thanexpected sales performance in overheated cities; and 2) unexpected speed of urbanization amid an improving economy.

DISCLAIMER:

This publication has been prepared by the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually, "Barclays"). It has been issued by one or more Barclays legal entities that are a part of the Investment Bank as provided below. It is provided to our clients for information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to any data included in this publication. Barclays will not treat unauthorized recipients of this report as its clients. Prices shown are indicative and Barclays is not offering to buy or sell or soliciting offers to buy or sell any financial instrument.

Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers, directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss of anticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication or its contents.

Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes to be reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever as to, the content of any third-party web site accessed via a hyperlink in this publication and such information is not incorporated by reference.

The views in this publication are those of the author(s) and are subject to change, and Barclays has no obligation to update its opinions or the information in this publication. The analyst recommendations in this publication reflect solely and exclusively those of the author(s), and such opinions were prepared independently of any other interests, including those of Barclays and/or its affiliates. This publication does not constitute personal investment advice or take into account the individual financial circumstances or objectives of the clients who receive it. The securities discussed herein may not be suitable for all investors. Barclays recommends that investors independently evaluate each issuer, security or instrument discussed herein and consult any independent advisors they believe necessary. The value of and income from any investment may fluctuate from day to day as a result of changes in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which may differ substantially from those reflected. Past performance is not necessarily indicative of future results.

This material has been issued and approved for distribution in the UK and European Economic Area by Barclays Bank PLC. It is being made available primarily to persons who are investment professionals as that term is defined in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005. It is directed at, and therefore should only be relied upon by, persons who have professional experience in matters relating to investments. The investments to which it relates are available only to such persons and will be entered into only with such persons. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and is a member of the London Stock Exchange.

The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA and SIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith accepts responsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.

Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulations permit otherwise.

Barclays Bank PLC, Paris Branch (registered in France under Paris RCS number 381 066 281) is regulated by the Autorité des marchés financiers and the Autorité de contrôle prudentiel. Registered office 34/36 Avenue de Friedland 75008 Paris.

This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and a Member of the Canadian Investor Protection Fund(CIPF).

Subject to the conditions of this publication as set out above, the Corporate & Investment Banking Division of Absa Bank Limited, an authorised financial services provider (Registration No.: 1986/004794/06. Registered Credit Provider Reg No NCRCP7), is distributing this material in South Africa. Absa Bank Limited is regulated by the South African Reserve Bank. This publication is not, nor is it intended to be, advice as defined and/or contemplated in the (South African) Financial Advisory and Intermediary Services Act, 37 of 2002, or any other financial, investment, trading, tax, legal, accounting, retirement, actuarial or other professional advice or service whatsoever. Any South African person or entity wishing to effect a transaction in any security discussed herein should do so only by contacting a representative of the Corporate & Investment Banking Division of Absa Bank Limited in South Africa, 15 Alice Lane, Sandton, Johannesburg, Gauteng 2196. Absa Bank Limited is a member of the Barclays group.

In Japan, foreign exchange research reports are prepared and distributed by Barclays Bank PLC Tokyo Branch. Other research reports are distributed to institutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan with registered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firm regulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143.

Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong Monetary Authority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

Information on securities/instruments that trade in Taiwan or written by a Taiwan-based research analyst is distributed by Barclays Capital Securities Taiwan Limited to its clients. The material on securities/instruments not traded in Taiwan is not to be construed as 'recommendation' in Taiwan. Barclays Capital Securities Taiwan Limited does not accept orders from clients to trade in such securities. This material may not be distributed to the public media or used by the public media without prior written consent of Barclays.

This material is distributed in South Korea by Barclays Capital Securities Limited, Seoul Branch.

All equity research material is distributed in India by Barclays Securities (India) Private Limited (SEBI Registration No: INB/INF 231292732 (NSE), INB/INF 011292738 (BSE) | Corporate Identification Number: U67120MH2006PTC161063 | Registered Office: 208 | Ceejay House | Dr. Annie Besant Road | Shivsagar Estate | Worli | Mumbai - 400 018 | India, Phone: + 91 22 67196363). Other research reports are distributed in India by Barclays Bank PLC, India Branch.

Barclays Bank PLC Frankfurt Branch distributes this material in Germany under the supervision of Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).

This material is distributed in Malaysia by Barclays Capital Markets Malaysia Sdn Bhd.

This material is distributed in Brazil by Banco Barclays S.A.

This material is distributed in Mexico by Barclays Bank Mexico, S.A.

Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principal place of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. Barclays

Bank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products or services are only available to Professional Clients, as defined by the Dubai Financial Services Authority.

Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bank incorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, Dubai (City) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi).

Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). Barclays Bank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar: Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or services are only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.

This material is distributed in the UAE (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC.

This material is distributed in Russia by OOO Barclays Capital, affiliated company of Barclays Bank PLC, registered and regulated in Russia by the FSFM. Broker License #177-11850-100000; Dealer License #177-11855-010000. Registered address in Russia: 125047 Moscow, 1st Tverskaya-Yamskaya str. 21.

This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore. For matters in connection with this report, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is One Raffles Quay Level 28, South Tower, Singapore 048583.

Barclays Bank PLC, Australia Branch (ARBN 062 449 585, AFSL 246617) is distributing this material in Australia. It is directed at 'wholesale clients' as defined by Australian Corporations Act 2001.

IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice. Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannot be used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or other matters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.

© Copyright Barclays Bank PLC (2015). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the prior written permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additional information regarding this publication will be furnished upon request.

US08-000001